ImmVira
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $100M
Overview
Clinical-stage biotech developing engineered oncolytic herpes simplex virus therapies for solid tumor cancers.
OncologyImmunology
Technology Platform
Genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) platform designed for selective tumor replication and immunostimulation through transgene expression.
Opportunities
Significant market opportunity in China's growing oncology therapeutics market and potential for global expansion through partnerships, with combination therapy approaches offering enhanced efficacy potential.
Risk Factors
Clinical development risks common to all novel biologics, regulatory uncertainty in emerging oncolytic virus field, and competition from established immuno-oncology therapies including checkpoint inhibitors and cell therapies.
Competitive Landscape
Competes with Amgen's T-VEC and other oncolytic virus developers; differentiation through engineered HSV platform with dual transgene expression of IL-12 and anti-PD-1 within single vector.